nifedipine extended release / Generic mfg. - LARVOL DELTA

Effect of nifedipine combined with magnesium sulfate on gestational hypertension and its impact on blood lipids. (PubMed, Blood Press Monit) - "Nifedipine combined with magnesium sulfate is more effective in managing GH. This regimen better improves blood pressure, hemorheological parameters, lipid profiles, and pregnancy outcomes, with good safety."

Journal • Cardiovascular • Dyslipidemia • Hypertension

ACE: Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension (clinicaltrials.gov) - P4 | N=70 | Completed | Sponsor: The University of Texas Health Science Center, Houston | Active, not recruiting ➔ Completed

HEOR • Trial completion • Cardiovascular • Gynecology • Hypertension

Targeted Antihypertensive Therapy After Hypertensive Pregnancy: Lactation-Safe Choices, Treatment Thresholds, and Outcomes (2015-2025). (PubMed, Curr Probl Cardiol) - "For lactating patients, nifedipine ER/amlodipine, enalapril, and labetalol are appropriate first-line choices; real-world data favor nifedipine for lowering readmissions. Scaling home BP monitoring with early follow-up improves outcomes. Large pragmatic RCTs comparing step-care strategies and tracking infant outcomes remain a priority."

Journal • Review • Cardiovascular • Hypertension

Rechallenge of 5-Fluorouracil in a Patient With Coronary Vasospasm Unable to Receive Oral Medications. (PubMed, JACC Case Rep) - "This case highlights the challenge of 5-FU rechallenge in patients unable to take oral prophylaxis. Transdermal nitroglycerin monotherapy proved insufficient, suggesting that intravenous prophylaxis may be required. Future studies should determine optimal strategies for preventing CV in patients with a similar presentation."

Journal • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor • HER-2

Non concordant side in concomitant Mild Autonomous Cortisol Secretion and Primary Aldosteronism: How should we prioritize treatment? (ENDO 2025) - "His medication regimen included Nifedipine XL 90 mg daily, Carvedilol 12.5 mg twice daily, Doxazosin 2 mg daily, Clonidine 0.1 mg daily, Eplerenone 100 mg twice daily, Losartan 50 mg daily, and Potassium 60 mEq daily...A 1 mg-dexamethasone suppression (DST) test revealed an elevated cortisol level (6.6 mcg/dL) and an appropriate dexamethasone level (255 ng/dL), consistent with Mild Autonomous Cortisol Secretion (MACS)... While surgical adrenalectomy may reverse cardiac remodeling in patients with PA and concurrent MACS, there is limited guidance on how to prioritize treatment when hormone excess originates from different adrenal glands. In such cases, clinical judgment and an individualized approach are essential, along with optimal medical management to mitigate long-term complications and risks."

Discordant • Adrenal Cortex Carcinoma • Cardiovascular • Congestive Heart Failure • Cushing’s Disease • Endocrine Cancer • Endocrine Disorders • Fatigue • Heart Failure • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Myocardial Infarction • Oncology • Orthopedics • Solid Tumor

Safety and Risks of Antihypertensive Medications During Breastfeeding: A Review of Current Guidelines. (PubMed, J Clin Med) - "Based on the available literature, calcium channel blockers (extended-release nifedipine as the first choice) and beta-blockers (labetalol, metoprolol) appear to be the drugs of choice. Our review highlights the need for further research to evaluate the long-term safety of antihypertensive medications during breastfeeding, improve clinical guidelines, and ensure optimal treatment for nursing mothers."

Journal • Review • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Optimizing pregnancy management of chronic hypertension: A case report of cerebrovascular accident in a pregnant woman and literature review. (PubMed, Medicine (Baltimore)) - "Pregnant women with chronic hypertension who present persistently elevated and uncontrollable blood pressure should be diagnosed with severe PE. Treatment regimens for hypertensive disorders of pregnancy typically involve oral antihypertensive medications, which should be administered judiciously based on clinical guidelines and trial evidence. For chronic maintenance treatment, labetalol and extended-release nifedipine are recommended as 1st-line agents by most international guidelines, with nifedipine being a viable initial option for severe hypertension. For women with severe PE, after corticosteroids have been administered for fetal lung maturation, an overall assessment of maternal and placental-fetal conditions should guide whether expectant management is feasible or if prompt delivery is required to minimize severe complications."

Journal • Review • Cardiovascular • Critical care • Gynecology • Hypertension

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Marshall University | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension

REPAIR: Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia (clinicaltrials.gov) - P=N/A | N=618 | Recruiting | Sponsor: Medical College of Wisconsin | Trial completion date: Jun 2030 ➔ Jun 2029 | Trial primary completion date: Jun 2029 ➔ Mar 2029

Trial completion date • Trial primary completion date • Cardiovascular • Gynecology • Hypertension

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy (clinicaltrials.gov) - P4 | N=110 | Not yet recruiting | Sponsor: University of California, Los Angeles

New P4 trial • Cardiovascular • Hypertension

IPAT: Intensive Postpartum Antihypertensive Treatment (clinicaltrials.gov) - P3 | N=60 | Active, not recruiting | Sponsor: Medical College of Wisconsin | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular

Evaluation of Aldosterone Suppression by Cinnarizine, a Putative Cav1.3 Inhibitor. (PubMed, J Clin Endocrinol Metab) - P=N/A | "A Cav1.3 ligand, cinnarizine, reduced aldosterone secretion from adrenocortical cells, but at maximum-soluble concentrations was less effective than the nonselective calcium blocker, nifedipine. At clinical doses, cinnarizine did not reduce plasma ARR in patients with PA, and, as in vitro, was inferior to nifedipine. The limited efficacy of high-dose nifedipine may be due to incomplete Cav1.3 blockade, or to a role for non-L-type calcium channels in aldosterone secretion."

Journal • Endocrine Disorders • CAV1

EVALUATING CHATGPT-4'S ACCURACY IN IDENTIFYING NEPHROLOGY MEDICATIONS FROM SELF-CAPTURED PILL IMAGES ACROSS MULTIPLE GPT-4 MODELS (ISN-WCN 2025) - "For instance, Nifedipine ER 90 mg was mistaken for Metformin Hydrochloride ER 500 mg due to a misreading of the imprint "NF 06" as "NF 05." Similar imprint-related errors were observed with Hydrochlorothiazide and Spironolactone. The ability to correct errors with feedback suggests that ChatGPT-4 could be valuable in digital health for medication identification, particularly when used under professional supervision. Future research should focus on enhancing the model's capacity to distinguish between similar imprints and improving its generalizability across a broader range of drug classes and image conditions, thereby advancing its utility in clinical practice."

Chronic Kidney Disease • Nephrology

Amlodipine versus Nifedipine ER for the Management of Postpartum Hypertension: A Noninferiority Randomized Controlled Trial. (PubMed, Am J Obstet Gynecol MFM) - P4 | "Amlodipine is non-inferior to nifedipine ER for postpartum hypertension treatment, as defined by median length of postpartum stay. Rates of side effects were similar between groups, but there was a statistically significant difference in medication discontinuation rates."

Head-to-Head • Journal • Cardiovascular • Gynecology • Hypertension • Hypotension • Obstetrics

Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum. (PubMed, Am J Perinatol) - "These findings suggest that BID dosing does not confer better blood pressure control in the antepartum or postpartum periods. Thus, daily dosing is reasonable and may be preferable for patient convenience and compliance."

Journal • Nephrology • Renal Disease

REPAIR: Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia (clinicaltrials.gov) - P=N/A | N=618 | Recruiting | Sponsor: Medical College of Wisconsin | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Gynecology • Hypertension

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension (clinicaltrials.gov) - P4 | N=175 | Completed | Sponsor: Prisma Health-Upstate | N=132 ➔ 175

Enrollment change • Head-to-Head • Cardiovascular • Hypertension

REPAIR: Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia (clinicaltrials.gov) - P=N/A | N=618 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Phase classification: P4 ➔ P=N/A

Phase classification • Cardiovascular • Gynecology • Hypertension

Identification of kidney-related medications using AI from self-captured pill images. (PubMed, Ren Fail) - "For instance, Nifedipine ER 90 mg was mistaken for Metformin Hydrochloride ER 500 mg because 'NF 06' was misread as 'NF 05'. Hydrochlorothiazide 50 mg was confused with the 25 mg version due to imprint errors, and Spironolactone 25 mg was misidentified as Naproxen Sodium or Diclofenac Sodium...Providing feedback improved accuracy, suggesting ChatGPT-4 could be a valuable tool in digital health for medication identification. Future research should enhance the model's ability to distinguish similar imprints and explore broader integration into digital health platforms."

Journal • Nephrology

REPAIR: Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia (clinicaltrials.gov) - P4 | N=618 | Not yet recruiting | Sponsor: Medical College of Wisconsin | Phase classification: P3 ➔ P4

Phase classification • Cardiovascular • Gynecology • Hypertension

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism (clinicaltrials.gov) - P=N/A | N=15 | Completed | Sponsor: Queen Mary University of London | Active, not recruiting ➔ Completed | Trial completion date: May 2024 ➔ Sep 2023 | Trial primary completion date: Apr 2024 ➔ Sep 2023

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Endocrine Disorders • Hypertension • CAV1

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial (clinicaltrials.gov) - P4 | N=600 | Recruiting | Sponsor: Nebraska Methodist Health System | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Gynecology • Hypertension

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Marshall University | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Apr 2024

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension

SCARPH: Safest Choice of Antihypertensive Regimen for Postpartum Hypertension (clinicaltrials.gov) - P3 | N=500 | Recruiting | Sponsor: Loma Linda University | Phase classification: P=N/A ➔ P3

Phase classification • Cardiovascular • Hypertension

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism (clinicaltrials.gov) - P=N/A | N=15 | Active, not recruiting | Sponsor: Queen Mary University of London | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ May 2024 | Trial primary completion date: Oct 2023 ➔ Apr 2024

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Endocrine Disorders • Hypertension • CAV1